Olmesartan Medoxomil in Hypertension and Renal Impairment
Efficacy and Safety of Olmesartan Medoxomil Compared With Losartan in Patients With Hypertension and Mild to Moderate Renal Impairment
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Darmstadt, Germany
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Mean sitting BP prior to randomization of 140-180/90-109 mmHg;
- Renal impairment prior to randomization of mild (50 ≤ CLcr ≥ 80 mL/min) to moderate (30 ≤ CLcr ≥50 mL/min) severity
Exclusion Criteria:
- Malignant hypertension or sitting BP greater than 180/109 mmHg;
- Severe heart failure, severe renal disease;
- Recent history of myocardial infarction, stroke or transient ischemic attack;
- History, clinical or current evidence of any significant gastrointestinal, respiratory, hematological, metabolic, immunological or any other underlying disease which in the opinion of the investigator would interfere with the patient's participation in the trial;
- Hypersensitivity or contraindications to ARBs or ACE inhibitors or any cross allergy;
- Treatment with dis-allowed medication;
- Pregnant or breastfeeding females or females of childbearing potential without adequate contraception;
- History of drug and/or alcohol abuse
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Olmesartan medoxomil
Olmesartan oral tablets 20 mg or 40 mg + losartan placebo.
Medications are taken once daily before breakfast with water.
|
Olmesartan oral tablets 20 or 40 mg + losartan placebo.
Medications are taken once daily before breakfast with water.
If its use is necessary, the dose of furosemide allowed is 20 to 120 mg per day at the discretion of the investigator
|
|
Experimental: Losartan
Losartan over encapsulated tablets 50 mg and 100 mg plus olmesartan placebo.
|
If its use is necessary, the dose of furosemide allowed is 20 to 120 mg per day at the discretion of the investigator
Medications are taken once daily before breakfast with water.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Change in mean sitting diastolic blood pressure (dBP), assessed by conventional blood pressure measurements after 12 weeks of treatment
Time Frame: Baseline to 12 weeks
|
Baseline to 12 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in mean sitting diastolic blood pressure, assessed by conventional blood pressure measurements after 1, 2, 3, 8, 18, 24, 30, 36, 44 and 52 weeks of treatment;
Time Frame: Baseline to 1, 2, 3, 8, 18, 24, 30, 36, 44 and 52 weeks
|
Baseline to 1, 2, 3, 8, 18, 24, 30, 36, 44 and 52 weeks
|
|
|
Change in mean sitting systolic blood pressure, assessed by conventional blood pressure measurements after 1, 2, 3, 8, 18, 24, 30, 36, 44 and 52 weeks of treatment;
Time Frame: Baseline to 1, 2, 3, 8, 18, 24, 30, 36, 44 and 52 weeks
|
Baseline to 1, 2, 3, 8, 18, 24, 30, 36, 44 and 52 weeks
|
|
|
Response to treatment after 1, 2, 4, 8, 12, 18, 24, 30, 36, 44 and 52 weeks of treatment;
Time Frame: Baseline to 1, 2, 4, 8, 12, 18, 24, 30, 36, 44 and 52 weeks
|
Response to treatment = mean sitting diastolic blood pressure less than or equal to 90 mmHg or reduction greater than or equal to 10 mmHg
|
Baseline to 1, 2, 4, 8, 12, 18, 24, 30, 36, 44 and 52 weeks
|
|
Changes in creatinine clearance after 12 and 52 weeks of treatment, changes in proteinuria after 4, 12, 24, 36 and 52 weeks of treatment;
Time Frame: Baseline to 12 and 52 weeks
|
Baseline to 12 and 52 weeks
|
|
|
Changes in serum creatinine after 12 and 52 weeks of treatment
Time Frame: Baseline to 12 and 52 weeks
|
Baseline to 12 and 52 weeks
|
|
|
Rate of patients per dose level after 12 and 52 weeks of treatment
Time Frame: Baseline to 12 and 52 weeks
|
Baseline to 12 and 52 weeks
|
|
|
Change in proteinuria after 4, 12, 24, 36 and 52 weeks of treatment
Time Frame: Baseline to 4, 12, 24, 36 and 52 weeks
|
Baseline to 4, 12, 24, 36 and 52 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: P. U. Witte, MD, PhD, IMFORM GmbH, Darmstadt, Germany
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Kidney Diseases
- Urologic Diseases
- Hypertension
- Renal Insufficiency
- Essential Hypertension
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Arrhythmia Agents
- Antihypertensive Agents
- Natriuretic Agents
- Membrane Transport Modulators
- Diuretics
- Angiotensin II Type 1 Receptor Blockers
- Angiotensin Receptor Antagonists
- Sodium Potassium Chloride Symporter Inhibitors
- Losartan
- Olmesartan
- Olmesartan Medoxomil
- Furosemide
Other Study ID Numbers
Other Study ID Numbers
- SE-866/43
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.